1. Search Result
Search Result
Results for "

GDF15

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

4

Inhibitory Antibodies

16

Recombinant Proteins

2

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99241
    Ponsegromab
    1 Publications Verification

    PF 06946860

    TGF-beta/Smad Cancer
    Ponsegromab is a Growth differentiation factor 15 (GDF15) inhibitor with human, cynomolgus monkey, and mouse target IC50 values of 0.123 nM, 0.053 nM, and 0.102 nM, respectively . Ponsegromab acts as a chemosensitizer, increases intracellular reactive oxygen species, reduces glutathione levels . Ponsegromab can be used for the research of oxaliplatin-resistant colorectal cancer .
    Ponsegromab
  • HY-P99100
    Visugromab
    2 Publications Verification

    CTL-002

    TGF-beta/Smad PD-1/PD-L1 Cancer
    Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Visugromab
  • HY-W587486

    Endogenous Metabolite Bacterial Neurological Disease
    N‑acetyltaurine is an orally active endogenous sulfonate that is synthesized from taurine and acetate in the renal cortex. N‑acetyltaurine supports bacterial growth as a sole fixed nitrogen or carbon source. N‑acetyltaurine buffers acetyl moieties of mitochondrial acetyl‑CoA in skeletal muscle. N‑acetyltaurine reduces food intake and body weight in obese and lean wild‑type mice in a GFRAL‑dependent manner. N‑acetyltaurine can be used for the research of diet‑induced obesity, hyperacetatemia and diabetes .
    N-Acetyltaurine
  • HY-149406

    AMPK Cancer
    AMPK activator 12 (compound 21) is a potent AMPK activator and GDF15 inducer. AMPK activator 12 increases GDF15 protein levels in human hepatic cells .
    AMPK activator 12
  • HY-RS16542

    Small Interfering RNA (siRNA) Others

    Gdf15 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gdf15 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gdf15 Mouse Pre-designed siRNA Set A
    Gdf15 Mouse Pre-designed siRNA Set A
  • HY-P991190

    AV-380

    TGF-beta/Smad Cancer
    Rilogrotug (AV-380) is a humanized IgG1 monoclonal antibody targeting GDF15 .
    Rilogrotug
  • HY-RS05352

    Small Interfering RNA (siRNA) Others

    GDF15 Human Pre-designed siRNA Set A contains three designed siRNAs for GDF15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    GDF15 Human Pre-designed siRNA Set A
    GDF15 Human Pre-designed siRNA Set A
  • HY-RS22974

    Small Interfering RNA (siRNA) Others

    Gdf15 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gdf15 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gdf15 Rat Pre-designed siRNA Set A
    Gdf15 Rat Pre-designed siRNA Set A
  • HY-P99100A

    CLT-002 (Powder)

    TGF-beta/Smad PD-1/PD-L1 Cancer
    Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Visugromab (Powder)
  • HY-183331

    Others Infection Inflammation/Immunology
    YXX0237 is an orally active anti-hypoxic agent. YXX0237 upregulates mRNA expression of FGF21 and GDF15 via activation of the ISR/ATF4 transcriptional axis. YXX0237 exhibits low cytotoxicity. YXX0237 enhances hypoxic survival in mice. YXX0237 can be used for the research of acute mountain sickness and hypoxia-related diseases .
    YXX0237
  • HY-183332

    Others Inflammation/Immunology
    YXX0248 is an orally active anti-hypoxic agent. YXX0248 upregulates mRNA expression of FGF21 and GDF15 via activation of the ISR/ATF4 transcriptional axis. YXX0248 exhibits low cytotoxicity. YXX0248 enhances hypoxic survival in mice. YXX0248 can be used for the research of acute mountain sickness and hypoxia-related diseases .
    YXX0248

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: